Economic analyses conducted in other countries can be taken into account but are not usually considered sufficient evidence upon which to base a decision. Economic studies undertaken by the pharmaceutical industry can also be taken into consideration but they are not considered sufficient. The current approach is to compare economic models during the period prior see more to reaching
a decision. Once validated by the Committee for Transmissible Diseases (CSMT), the recommendations are published on the HCSP website and sent to the Minister of Health, who ultimately decides whether the CTV recommendations will be incorporated into the new vaccination schedule (Fig. 1). The vaccination schedules are updated annually and published in the official bulletin of the Ministry of Health. They are then published in the special annual issue of the Bulletin Épidémiologique Hebdomadaire (BEH; a weekly epidemiological bulletin published by INVS), the bulletin of the Conseil National de l’Ordre des Médecins (CNOM; the main professional organization for physicians), the bulletin of the Comité d’Éducation Sanitaire et Sociale de la Pharmacie Française (the Permanent Committee of the National Selleckchem INCB024360 Order of Pharmacists), the Vidal (French dictionary
of pharmaceuticals), and other medical media, as well as in children’s health textbooks. When a vaccine has been recommended by CTV, the Commission for Transparency, which is a part of HAS, evaluates the impact of the administration of this vaccine on public health services (e.g., increase in rendered medical services). This evaluation will be used to determine the level of reimbursement
(usually 65%) and will serve as a basis for negotiation of the vaccine’s price between the vaccine manufacturer and the CEPS (Comité Economique des Produits de Santé or Health Products Evaluation Committee). Then the government will decide whether or not the new recommendation no will be integrated into the French immunization schedule. The French government is not obliged to implement the CTV recommendations, although it has previously implemented most of them. Currently, vaccines recommended for the general population are subject to reimbursement. Some vaccines recommended for targeted use are not subject to reimbursement (e.g., hepatitis A vaccine for travellers or chickenpox vaccine for adolescents). The Ministry of Finance also plays a role in the decision making but the extent of its influence is unclear to many. The Caisse Nationale d’Assurance Maladie (CNAM), or the National Health Insurance Fund, is a public-sector organization and is represented by ex-officio members of the CTV. The CNAM is a major player since it provides reimbursements for vaccines (seasonal flu vaccines, as well as vaccines against measles, mumps and rubella) but it does not interfere with the decision making process.